Syntara Completes Recruitment for Phase 2 Trial of SNT-4728 in Isolated REM Sleep Behaviour Disorder (iRBD)
Source: Kapitales Research
Key Highlights:
The final patient has been enrolled in Syntara’s Phase 2 clinical trial for SNT-4728, a first-in-class neuro-targeted anti-inflammatory therapy.
The trial seeks to evaluate the treatment’s ability to reduce neuroinflammation linked to neurodegenerative diseases.
iRBD, which affects 2% of individuals over 50, is a major risk factor for progression to diseases such as Parkinson’s and Dementia with Lewy bodies.
The trial results are expected to be available in the second quarter of 2026.
Recruitment Completed for Phase 2 Study
Syntara Limited (ASX: SNT) has successfully completed the recruitment phase for its randomised, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728. The study focuses on patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition linked to a high risk of progression to neurodegenerative diseases like Parkinson's.
The trial is being conducted in collaboration with academic centres, supported by Parkinson's UK through its Parkinson's Virtual Biotech program, and is expected to yield important data on SNT-4728’s ability to reduce neuroinflammation and potentially slow the progression of neurodegenerative diseases.
iRBD and Neurodegenerative Disease Link
iRBD is estimated to affect around 2% of individuals over the age of 50. Studies over the long term indicate that nearly 90% of individuals with iRBD eventually develop conditions like Parkinson’s disease or dementia with Lewy bodies. This highlights a substantial unmet medical need for effective treatments aimed at slowing or preventing disease progression.
The study will assess both the safety of SNT-4728 and its ability to reduce inflammation in brain regions linked to the progression of diseases like Parkinson’s. The use of advanced brain imaging will allow for a comprehensive evaluation of the therapy’s impact on neuroinflammation.
Key Study Objectives and Endpoints
The Phase 2 trial is designed to assess SNT-4728 across two important areas:
Reduction in Neuroinflammation: Using brain imaging techniques before and after 12 weeks of treatment, the study aims to evaluate whether SNT-4728 can reduce neuroinflammation in regions of the brain implicated in the progression of neurodegenerative diseases.
Improvement of iRBD Symptoms: As an exploratory secondary endpoint, the study will also assess whether SNT-4728 improves clinical symptoms of iRBD.
A positive outcome from this study would not only demonstrate symptom relief but also provide critical insights into the potential of SNT-4728 to modify disease biology at an early stage, offering hope for patients with limited treatment options.
Statement from Experts
Professor Simon Lewis, Director of the Parkinson’s Disease Research Clinic at Macquarie University, commented, "A positive outcome from this study could potentially change the field. Demonstrating an improvement in iRBD symptoms would offer immediate hope to patients in a condition where treatment options are currently very limited."
He further emphasized that evidence of SNT-4728 reducing neuroinflammation would provide valuable insight into whether early intervention could alter the course of neurodegenerative diseases.
CEO’s Remarks
Syntara’s CEO, Gary Phillips, expressed his gratitude to the principal investigators, the study staff, and the patients who participated in the trial. He recognised the complexity of the study and expressed gratitude for the commitment of all those involved in its successful execution. Phillips also thanked the teams involved in conducting nationwide PET imaging for the study’s Australian component.
Ongoing Clinical Program
The iRBD Phase 2 trial is just one of several clinical programs underway at Syntara. The company is anticipating five key data readouts across its pipeline in 2026, with the results from this trial expected to be a significant milestone in advancing SNT-4728 and related therapies.
Conclusion
The completion of patient recruitment marks an important step forward for Syntara in its mission to develop treatments targeting neurodegenerative diseases. With top-line results expected in the second quarter of 2026, the company is poised to provide new insights into the potential of SNT-4728 to improve outcomes for patients with iRBD and potentially slow the progression to Parkinson’s disease.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Syntara Completes Recruitment for Phase 2 Trial of SNT-4728 in Isolated REM Sleep Behaviour Disorder (iRBD)
Key Highlights:
Recruitment Completed for Phase 2 Study
Syntara Limited (ASX: SNT) has successfully completed the recruitment phase for its randomised, double-blind, placebo-controlled Phase 2 clinical trial of SNT-4728. The study focuses on patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition linked to a high risk of progression to neurodegenerative diseases like Parkinson's.
The trial is being conducted in collaboration with academic centres, supported by Parkinson's UK through its Parkinson's Virtual Biotech program, and is expected to yield important data on SNT-4728’s ability to reduce neuroinflammation and potentially slow the progression of neurodegenerative diseases.
iRBD and Neurodegenerative Disease Link
iRBD is estimated to affect around 2% of individuals over the age of 50. Studies over the long term indicate that nearly 90% of individuals with iRBD eventually develop conditions like Parkinson’s disease or dementia with Lewy bodies. This highlights a substantial unmet medical need for effective treatments aimed at slowing or preventing disease progression.
The study will assess both the safety of SNT-4728 and its ability to reduce inflammation in brain regions linked to the progression of diseases like Parkinson’s. The use of advanced brain imaging will allow for a comprehensive evaluation of the therapy’s impact on neuroinflammation.
Key Study Objectives and Endpoints
The Phase 2 trial is designed to assess SNT-4728 across two important areas:
A positive outcome from this study would not only demonstrate symptom relief but also provide critical insights into the potential of SNT-4728 to modify disease biology at an early stage, offering hope for patients with limited treatment options.
Statement from Experts
Professor Simon Lewis, Director of the Parkinson’s Disease Research Clinic at Macquarie University, commented, "A positive outcome from this study could potentially change the field. Demonstrating an improvement in iRBD symptoms would offer immediate hope to patients in a condition where treatment options are currently very limited."
He further emphasized that evidence of SNT-4728 reducing neuroinflammation would provide valuable insight into whether early intervention could alter the course of neurodegenerative diseases.
CEO’s Remarks
Syntara’s CEO, Gary Phillips, expressed his gratitude to the principal investigators, the study staff, and the patients who participated in the trial. He recognised the complexity of the study and expressed gratitude for the commitment of all those involved in its successful execution. Phillips also thanked the teams involved in conducting nationwide PET imaging for the study’s Australian component.
Ongoing Clinical Program
The iRBD Phase 2 trial is just one of several clinical programs underway at Syntara. The company is anticipating five key data readouts across its pipeline in 2026, with the results from this trial expected to be a significant milestone in advancing SNT-4728 and related therapies.
Conclusion
The completion of patient recruitment marks an important step forward for Syntara in its mission to develop treatments targeting neurodegenerative diseases. With top-line results expected in the second quarter of 2026, the company is poised to provide new insights into the potential of SNT-4728 to improve outcomes for patients with iRBD and potentially slow the progression to Parkinson’s disease.
Disclaimer for Kapitales Research
The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au